Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 57, Issue 6, 2008, Pages 796-801

  Tribble, Diane L ^a   Farnier, Michel ^b   Macdonell, Geraldine ^a   Perevozskaya, Inna ^a   Davies, Michael J ^a   Gumbiner, Barry ^a   Musliner, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Point Medical   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLACEBO; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GEL ELECTROPHORESIS; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARTICLE SIZE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PARTICLE SIZE; PROCETOFEN; TRIGLYCERIDES;

EID: 43849104295     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.01.026     Document Type: Article

References (28)

1. Farnier M., Freeman M., Macdonell G., et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 26 (2005) 897-905
2. McKenney J.M., Farnier M., Lo K.W., et al. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
3. Fazio S., and Linton M.F. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 6 (2004) 148-157
4. Carmena R., Duriez P., and Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109 Suppl 1 (2004) III2-III7
5. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
6. Kulkarni K.R., Garber D.W., Marcovina S.M., et al. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 35 (1994) 159-168
7. Ose L., Reyes R., Johnson-Levonas A.O., et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 29 (2007) 2419-2432
8. Kulkarni K.R., Marcovina S.M., Krauss R.M., et al. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J Lipid Res 38 (1997) 2353-2364
9. Kulkarni K.R., Garber D.W., Jones M.K., et al. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res 36 (1995) 2291-2302
10. Connover W.J. Practical nonparametric statistics (1999), John Wiley & Sons, New York
11. Iglewicz B. Robust scale estimators and confidence intervals for location. In: Hoaglin D.C., Mosteller F., and Tukey J.W. (Eds). Understanding robust and exploratory data analysis (1983), John Wiley & Sons, New York 404-432
12. Durrington P. Dyslipidaemia. Lancet 362 (2003) 717-731
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
14. Rizzo M., and Berneis K. The clinical significance of the size of low-density lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 23 (2007) 1103-1111
15. Feher M.D., Caslake M., Foxton J., et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 15 (1999) 395-399
16. Krauss R.M., Lindgren F.T., Williams P.T., et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 2 (1987) 62-66
17. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
18. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
19. Gardner C.D., Fortmann S.P., and Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
20. Mack W.J., Krauss R.M., and Hodis H.N. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 16 (1996) 697-704
21. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102 (2000) 1886-1892
22. Goff Jr. D.C., D'Agostino Jr. R.B., Haffner S.M., et al. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 54 (2005) 264-270
23. Ballantyne F.C., Clark R.S., Simpson H.S., et al. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism 31 (1982) 433-437
24. Tatami R., Mabuchi H., Ueda K., et al. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 64 (1981) 1174-1184
25. Rizzo M., and Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 99 (2006) 1-14
26. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
27. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
28. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245